Janvier Group Biosciences has acquired Firalis Molecular Precision (FMP) for an undisclosed amount. FMP, a fast-growing Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), specializes in providing advanced and tailored BioAnalytical Testing services to the Life Sciences sector. With operations in Huningue, France, and Cambridge, USA, FMP has established itself as a key partner in drug development.
Firalis Molecular Precision's team leverages extensive scientific expertise and cutting-edge in-house platforms to deliver a comprehensive suite of services. These include sample storage and management, bioanalytical testing, omic data analysis and interpretation, and assay development and production. FMP's mission centers on equipping healthcare professionals, researchers, and biopharmaceutical organizations with the essential solutions needed to advance patient care and foster personalized medicine through high-quality data.
This strategic acquisition is set to significantly expand Janvier Group Biosciences' capabilities and market footprint within the global life sciences industry. The integration of FMP's specialized bioanalytical testing and omic data expertise is expected to enhance Janvier's service portfolio, allowing for a more comprehensive offering across the entire drug development process. The move also broadens Janvier's geographical presence, incorporating FMP's established bases in Europe and North America.
The combination of Janvier Group Biosciences and Firalis Molecular Precision aims to create a more robust entity, better equipped to support clients from early-stage research through clinical development. By integrating FMP's precision services, the combined organization is poised to accelerate progress towards innovative healthcare solutions and more personalized therapeutic approaches for patients worldwide.